Terns Pharmaceuticals Ownership | Who Owns Terns Pharmaceuticals?

Terns Pharmaceuticals Ownership Summary

Terns Pharmaceuticals is owned by 105.30% institutional investors, 0.26% insiders. Soleus capital management is the largest institutional shareholder, holding 10.46% of TERN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.39% of its assets in Terns Pharmaceuticals shares.

TERN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Terns Pharmaceuticals	105.30%	0.26%	-5.56%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Soleus capital management	8.14M	10.46%	$45.11M
Orbimed advisors	7.56M	9.72%	$41.90M
Vivo capital	6.90M	8.86%	$38.20M
Blackrock funding, inc. /de	5.74M	7.38%	$31.82M
Deep track capital, lp	5.58M	7.17%	$30.89B
Schonfeld strategic advisors	4.75M	6.11%	$26.32M
Blackrock	4.12M	5.53%	$28.06M
Vanguard group	3.87M	4.97%	$21.44M
Nuveen asset management	2.63M	3.38%	$14.59M
Candriam s.c.a.	2.15M	2.77%	$11.93M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Superstring capital management lp	2.02M	9.69%	$11.19M
Vivo capital	6.90M	4.28%	$38.20M
Soleus capital management	8.14M	2.83%	$45.11M
Acuta capital partners	447.50K	2.49%	$2.48B
Timessquare capital management	621.64K	1.45%	$92.18M
Robeco schweiz	411.27K	1.17%	$60.99M
Deep track capital, lp	5.58M	1.15%	$30.89B
Orbimed advisors	7.56M	0.86%	$41.90M
Altium capital management lp	475.00K	0.75%	$2.63M
Parkman healthcare partners	829.11K	0.61%	$4.59M

Top Buyers

Holder	Shares	% Assets	Change
Candriam s.c.a.	2.15M	0.07%	2.15M
Soleus capital management	8.14M	2.83%	1.92M
Schonfeld strategic advisors	4.75M	0.15%	1.46M
Blackrock funding, inc. /de	5.74M	0.00%	1.04M
Norges bank	849.39K	0.00%	849.39K

Top Sellers

Holder	Shares	% Assets	Change
Vr adviser	1.08M	0.41%	-2.33M
Avidity partners management lp	-	-	-2.13M
Janus henderson group	-	-	-2.00M
Exoduspoint capital management, lp	10.82K	0.00%	-1.64M
Point72 asset management	1.25M	0.02%	-1.46M

New Positions

Holder	Shares	% Assets	Change	Value
Candriam s.c.a.	2.15M	0.07%	2.15M	$11.93M
Norges bank	849.39K	0.00%	849.39K	$4.71M
Bnp paribas arbitrage, snc	224.26K	0.00%	224.26K	$1.24M
Hightower advisors	84.43K	0.00%	84.43K	$467.74K
Crestline management, lp	66.60K	0.01%	66.60K	$368.96K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-9.00
Pnc financial services group	-17.00
Capital performance advisors llp	-23.00
Farther finance advisors	-27.00
Versant capital management	-36.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	149	-9.70%	81,944,156	3.09%	105	1.01%	94	-8.74%	31	-18.42%
Sep 30, 2024	165	17.86%	79,491,270	19.38%	102	1.28%	103	8.42%	38	65.22%
Jun 30, 2024	140	19.66%	66,584,833	5.52%	89	1.24%	95	48.44%	23	-28.13%
Mar 31, 2024	117	6.36%	63,102,304	-0.76%	84	1.10%	64	4.92%	32	39.13%
Dec 31, 2023	110	12.24%	63,584,999	3.76%	87	1.20%	61	48.78%	23	-36.11%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	2.09M	2.39%	792.70K
Vanguard Total Stock Mkt Idx Inv	2.07M	2.38%	-
iShares Russell 2000 ETF	1.87M	2.14%	-16.17K
Belfius Equities Cure C Cap	1.29M	1.48%	-
CREF Stock R1	1.24M	1.42%	-182.50K
Fidelity Select Biotechnology	1.09M	1.29%	1.09M
CREF Stock R3	1.08M	1.23%	-160.00K
US Small-Cap Growth II Equity Comp	1.04M	1.23%	529.45K
T. Rowe Price New Horizons	1.04M	1.23%	-
Vanguard Institutional Extnd Mkt Idx Tr	936.97K	1.08%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 01, 2025	Kuriakose Emil	Chief Medical Officer	Sell	$2.37K
Nov 30, 2024	Jung Melita Sun	Chief Business Officer	Buy	$11.50K
Nov 30, 2024	Burroughs Amy L.	Chief Executive Officer	Buy	$2.61K
Jan 02, 2025	Kuriakose Emil	Chief Medical Officer	Sell	$25.61K
Jan 06, 2025	Vignola Mark J.	Chief Financial Officer	Sell	$52.50K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	1
2025 Q1	-	5
2024 Q4	1	-
2024 Q3	2	18
2024 Q2	2	9

TERN Ownership FAQ

Who Owns Terns Pharmaceuticals?

Terns Pharmaceuticals shareholders are primarily institutional investors at 105.30%, followed by 0.26% insiders and -5.56% retail investors. The average institutional ownership in Terns Pharmaceuticals's industry, Biotech Stocks , is 68.48%, which Terns Pharmaceuticals exceeds.

Who owns the most shares of Terns Pharmaceuticals?

Terns Pharmaceuticals’s largest shareholders are Soleus capital management (8.14M shares, 10.46%), Orbimed advisors (7.56M shares, 9.72%), and Vivo capital (6.9M shares, 8.86%). Together, they hold 29.04% of Terns Pharmaceuticals’s total shares outstanding.

Does Blackrock own Terns Pharmaceuticals?

Yes, BlackRock owns 5.53% of Terns Pharmaceuticals, totaling 4.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 28.06M$. In the last quarter, BlackRock increased its holdings by 804.98K shares, a 24.28% change.

Who is Terns Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Superstring capital management lp is Terns Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 9.69% of its assets in 2.02M Terns Pharmaceuticals shares, valued at 11.19M$.

Who is the top mutual fund holder of Terns Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Terns Pharmaceuticals shares, with 2.39% of its total shares outstanding invested in 2.09M Terns Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools